(Q54609654)

1 June 2018

title

RGS4 genotype is not associated with antipsychotic medication response in schizophrenia. (English)

1 reference

1 June 2018

0 references

1

1 reference

1 June 2018

author name string

A Illi

2

1 reference

1 June 2018

K Hänninen

3

1 reference

1 June 2018

H Katila

4

1 reference

1 June 2018

S Anttila

5

1 reference

1 June 2018

R Rontu

6

1 reference

1 June 2018

K M Mattila

7

1 reference

1 June 2018

E Leinonen

8

1 reference

1 June 2018

T Lehtimäki

9

1 reference

1 June 2018

publication date

11 April 2006

1 reference

1 June 2018

Journal of Neural Transmission

published in

1 reference

1 June 2018

volume

113

1 reference

1 June 2018

issue

10

1 reference

1 June 2018

page(s)

1563-1568

1 reference

1 June 2018

https://scigraph.springernature.com/pub.10.1007/s00702-006-0445-2

exact match

0 references

cites work

Failure to confirm association between RGS4 haplotypes and schizophrenia in Caucasians

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00702-006-0445-2

Regional expression of RGS4 mRNA in human brain

21 January 2018

1 reference

12 December 2020

Dopamine receptor-mediated regulation of RGS2 and RGS4 mRNA differentially depends on ascending dopamine projections and time

1 reference

12 December 2020

Association and linkage analyses of RGS4 polymorphisms in schizophrenia

1 reference

12 December 2020

Support for RGS4 as a susceptibility gene for schizophrenia

1 reference

12 December 2020

Regulator of G-protein signaling 4 (RGS4) gene is associated with schizophrenia in Irish high density families

1 reference

12 December 2020

Regulators of G-protein signalling as new central nervous system drug targets.

1 reference

12 December 2020

Differential effects of regulator of G protein signaling (RGS) proteins on serotonin 5-HT1A, 5-HT2A, and dopamine D2 receptor-mediated signaling and adenylyl cyclase activity

1 reference

12 December 2020

Confirming RGS4 as a susceptibility gene for schizophrenia

1 reference

12 December 2020

Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions

1 reference

12 December 2020

Allelic discrimination using fluorogenic probes and the 5' nuclease assay

1 reference

12 December 2020

Dynamic expression of RGS4 in the developing nervous system and regulation by the neural type-specific transcription factor Phox2b.

1 reference

12 December 2020

Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients

1 reference

12 December 2020

Regulators of G protein signaling (RGS proteins): novel central nervous system drug targets

1 reference

12 December 2020

Physiological actions of regulators of G-protein signaling (RGS) proteins

1 reference

12 December 2020

Association and linkage analysis of RGS4 polymorphisms with schizophrenia and bipolar disorder in Brazil.

1 reference

12 December 2020

Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia

1 reference

12 December 2020

Structure-based design, synthesis, and pharmacologic evaluation of peptide RGS4 inhibitors.

1 reference

12 December 2020

TRANSFAC: transcriptional regulation, from patterns to profiles

1 reference

12 December 2020

Selective expression of regulators of G-protein signaling (RGS) in the human central nervous system

1 reference

12 December 2020

Opposite modulation of regulators of G protein signalling-2 RGS2 and RGS4 expression by dopamine receptors in the rat striatum

1 reference

12 December 2020

Identification of novel ErbB3-interacting factors using the split-ubiquitin membrane yeast two-hybrid system

1 reference

12 December 2020

A glutamatergic deficiency model of schizophrenia

1 reference

12 December 2020

10.1007/S00702-006-0445-2

Identifiers

DOI

1 reference

1 June 2018

1 reference

1 June 2018